In the initial clinical trial one refractory AML patient was treated with CD33-CAR-Ts which caused a marked decrease in BM blast level within two weeks, but gradual increase in blast level was observed by three weeks post infusion [82]. Here, CD33 is linked to acute myeloid leukemia.